Stereotactic Radiation Therapy in Treating Patients With Advanced Liver Cancer
Feasibility of Hypofractionated Stereotactic Radiotherapy in Patients With Hepatocellular Carcinoma
Sponsor: National Cancer Institute (NCI)
A NA clinical study on Liver Cancer, this trial is completed. The trial is conducted by National Cancer Institute (NCI) and has accumulated 10 data snapshots since 2007. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
10 versions recorded-
Dec 2024 — Present [monthly]
Completed NA
-
Sep 2024 — Dec 2024 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2024 — Jul 2024 [monthly]
Completed NA
-
Nov 2023 — Jan 2024 [monthly]
Completed NA
Phase: PHASE1 → NA
▶ Show 5 earlier versions
-
Jan 2021 — Nov 2023 [monthly]
Completed PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
-
Oct 2017 — Jun 2018 [monthly]
Completed PHASE1
Status: Unknown Status → Completed
-
Feb 2017 — Oct 2017 [monthly]
Unknown Status PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status PHASE1
First recorded
Nov 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
- University of Nebraska
For direct contact, visit the study record on ClinicalTrials.gov .